Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates
Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.
You may also be interested in...
Terlivaz Approved By FDA As Mallinckrodt Seeks To Advance New Business Strategy
Terlivaz is the first product approved to improve kidney function in adults with hepatorenal syndrome (HRS). The approval is a milestone in a long regulatory road for the drug.
Nielsen Follows Olafsson From Hikma Under Mallinckrodt Shake-Up
After emerging successfully from bankruptcy proceedings, and appointing the thoroughly experienced Siggi Olafsson as its CEO, Mallinckrodt has unveiled a new senior leadership team.
Mallinckrodt Finalizes Bankruptcy Filing And Opioid, Acthar Settlements
The company will pay $1.6bn to settle opioid litigation and $260m to settle a Medicaid rebate dispute related to Acthar Gel under a restructuring support agreement.